Literature DB >> 25769721

miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells.

Jing Zhang1, Jingjing Jiao1, Silvia Cermelli2, Kyle Muir2, Kwang Hwa Jung1, Ruhai Zou3, Asif Rashid4, Mihai Gagea5, Sonya Zabludoff6, Raghu Kalluri7, Laura Beretta8.   

Abstract

miR-21 is upregulated in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, where it is associated with poor prognosis. Here, we offer preclinical evidence that miR-21 offers a therapeutic and chemopreventive target in these liver cancers. In mice with hepatic deletion of Pten, anti-miR-21 treatment reduced liver tumor growth and prevented tumor development. These effects were accompanied with a decrease in liver fibrosis and a concomitant reduction of CD24(+) liver progenitor cells and S100A4(+) cancer-associated stromal cells. Notch2 inhibition also occurred in tumors following anti-miR-21 treatment. We further showed that miR-21 is necessary for the survival of CD24(+) progenitor cells, a cellular phenotype mediated by Notch2, osteopontin, and integrin αv. Our results identify miR-21 as a key regulator of tumor-initiating cell survival, malignant development, and growth in liver cancer, highlighting the role of CD24(+) cells in the expansion of S100A4(+) cancer-associated stromal cells and associated liver fibrosis. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25769721      PMCID: PMC4603420          DOI: 10.1158/0008-5472.CAN-14-1254

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  miR-21 is a critical therapeutic target for renal fibrosis.

Authors:  Yong He; Cheng Huang; Jun Li
Journal:  Cell Biochem Biophys       Date:  2014-04       Impact factor: 2.194

2.  Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans.

Authors:  Rebecca T Marquez; Sarmistha Bandyopadhyay; Erik B Wendlandt; Kathy Keck; Brandon A Hoffer; Michael S Icardi; Randolph N Christensen; Warren N Schmidt; Anton P McCaffrey
Journal:  Lab Invest       Date:  2010-07-12       Impact factor: 5.662

3.  Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes.

Authors:  Sayaka Sekiya; Atsushi Suzuki
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

4.  MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3.

Authors:  Florin M Selaru; Alexandru V Olaru; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Jian Yang; Bogdan Paun; Zhe Jin; Rachana Agarwal; James P Hamilton; John Abraham; Christos Georgiades; Hector Alvarez; Perumal Vivekanandan; Wayne Yu; Anirban Maitra; Michael Torbenson; Paul J Thuluvath; Gregory J Gores; Nicholas F LaRusso; Ralph Hruban; Stephen J Meltzer
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

5.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

Authors:  Yasuo Horie; Akira Suzuki; Ei Kataoka; Takehiko Sasaki; Koichi Hamada; Junko Sasaki; Katsunori Mizuno; Go Hasegawa; Hiroyuki Kishimoto; Masahiro Iizuka; Makoto Naito; Katsuhiko Enomoto; Sumio Watanabe; Tak Wah Mak; Toru Nakano
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

6.  Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer.

Authors:  Dennis Löffler; Katja Brocke-Heidrich; Gabriele Pfeifer; Claudia Stocsits; Jörg Hackermüller; Antje K Kretzschmar; Renate Burger; Martin Gramatzki; Conny Blumert; Kay Bauer; Helena Cvijic; A Kerstin Ullmann; Peter F Stadler; Friedemann Horn
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

7.  MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma.

Authors:  Liang Zhou; Zhao-Xu Yang; Wen-Jie Song; Qing-Jun Li; Fan Yang; De-Sheng Wang; Ning Zhang; Ke-Feng Dou
Journal:  Int J Oncol       Date:  2013-05-27       Impact factor: 5.650

8.  Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.

Authors:  Jinmai Jiang; Yuriy Gusev; Ileana Aderca; Teresa A Mettler; David M Nagorney; Daniel J Brackett; Lewis R Roberts; Thomas D Schmittgen
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

9.  Constitutive Notch2 signaling induces hepatic tumors in mice.

Authors:  Michael T Dill; Luigi Tornillo; Thorsten Fritzius; Luigi Terracciano; David Semela; Bernhard Bettler; Markus H Heim; Jan S Tchorz
Journal:  Hepatology       Date:  2013-03-14       Impact factor: 17.425

10.  microRNA are Central Players in Anti- and Profibrotic Gene Regulation during Liver Fibrosis.

Authors:  Andrea Noetel; Monika Kwiecinski; Natalia Elfimova; Jia Huang; Margarete Odenthal
Journal:  Front Physiol       Date:  2012-03-19       Impact factor: 4.566

View more
  28 in total

1.  Is miR-21 a potent target for liver fibrosis?

Authors:  Sanchuan Lai; Yasuko Iwakiri
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

Review 2.  The role of miRNAs in cholangiocarcinoma.

Authors:  Jessica A Howell; Shahid A Khan
Journal:  Hepat Oncol       Date:  2016-03-29

3.  Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.

Authors:  Kwang Hwa Jung; Wonbeak Yoo; Heather L Stevenson; Dipti Deshpande; Hong Shen; Mihai Gagea; Suk-Young Yoo; Jing Wang; T Kris Eckols; Uddalak Bharadwaj; David J Tweardy; Laura Beretta
Journal:  Clin Cancer Res       Date:  2017-05-22       Impact factor: 12.531

4.  MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis.

Authors:  Jorge Matias Caviglia; Jun Yan; Myoung-Kuk Jang; Geum-Youn Gwak; Silvia Affo; Lexing Yu; Peter Olinga; Richard A Friedman; Xin Chen; Robert F Schwabe
Journal:  Hepatology       Date:  2018-01-18       Impact factor: 17.425

5.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 6.  Role of MicroRNAs in NAFLD/NASH.

Authors:  Gyongyi Szabo; Timea Csak
Journal:  Dig Dis Sci       Date:  2016-01-14       Impact factor: 3.199

Review 7.  Dairy consumption and hepatocellular carcinoma risk.

Authors:  Bodo C Melnik
Journal:  Ann Transl Med       Date:  2021-04

Review 8.  MiR-21: an environmental driver of malignant melanoma?

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2015-06-27       Impact factor: 5.531

9.  Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis.

Authors:  Kwang Hwa Jung; Jing Zhang; Chong Zhou; Hong Shen; Mihai Gagea; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; Laura Beretta
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

10.  Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population.

Authors:  Talita Duarte-Salles; Sandeep Misra; Magdalena Stepien; Amelie Plymoth; David Muller; Kim Overvad; Anja Olsen; Anne Tjønneland; Laura Baglietto; Gianluca Severi; Marie-Christine Boutron-Ruault; Renee Turzanski-Fortner; Rudolf Kaaks; Heiner Boeing; Krasimira Aleksandrova; Antonia Trichopoulou; Pagona Lagiou; Christina Bamia; Valeria Pala; Domenico Palli; Amalia Mattiello; Rosario Tumino; Alessio Naccarati; H B As Bueno-de-Mesquita; Petra H Peeters; Elisabete Weiderpass; J Ramón Quirós; Antonio Agudo; Emilio Sánchez-Cantalejo; Eva Ardanaz; Diana Gavrila; Miren Dorronsoro; Mårten Werner; Oskar Hemmingsson; Bodil Ohlsson; Klas Sjöberg; Nicholas J Wareham; Kay-Tee Khaw; Kathryn E Bradbury; Marc J Gunter; Amanda J Cross; Elio Riboli; Mazda Jenab; Pierre Hainaut; Laura Beretta
Journal:  Cancer Prev Res (Phila)       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.